Aprea Therapeutics to Join 2024 RBC Capital Markets Healthcare Conference

28 June 2024

DOYLESTOWN, Pa., May 13, 2024 – Aprea Therapeutics (Nasdaq: APRE), a biopharmaceutical company specializing in precision oncology, announced its participation in the upcoming 2024 RBC Capital Markets Global Healthcare Conference. This event is scheduled for May 14-15, 2024, in New York, NY. Company representatives will be available for one-on-one meetings during the conference.

Aprea Therapeutics is a clinical-stage company headquartered in Doylestown, Pennsylvania. The company focuses on developing treatments for cancer using synthetic lethality, a process that targets specific genetic vulnerabilities within cancer cells. Their main drug candidate, ATRN-119, is an ATR inhibitor aimed at treating solid tumors. ATRN-119 is currently in the clinical trial phase.

Additionally, Aprea has advanced its WEE1 inhibitor program, with its lead compound APR-1051. This oral, small molecule drug has completed all necessary preclinical studies and has received clearance from the FDA to proceed with clinical trials.

Aprea emphasizes its commitment to precision oncology, leveraging advances in genetic research to create targeted therapies. Their approach aims to exploit the inherent weaknesses in cancer cells, offering potentially more effective and less toxic treatment options.

The management team at Aprea is keen on utilizing events like the RBC Capital Markets Global Healthcare Conference to engage with investors, share updates on their clinical programs, and explore potential collaborations. The conference provides a platform for the company to showcase its innovative research and development efforts in the field of oncology.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!